Trading Update

Dechra Pharmaceuticals PLC
09 January 2006






Issued by Citigate Dewe Rogerson Limited, Birmingham
Date: Monday, 9 January 2006

                                                               Embargoed: 7.00am

                           Dechra Pharmaceuticals PLC
                     Product Development and Trading Update

Dechra Pharmaceuticals PLC ('the Group') issues the following update to
shareholders, ahead of publication of the Group's Interim results for the six
months ended 31 December 2005, which are scheduled to be announced on Tuesday 28
February 2006.

Product Development Update

Our strategic focus continues to be the ongoing development of our own
veterinary pharmaceutical products.

It is pleasing to report that through the mutual recognition procedure, we have
gained approval for Vetoryl Capsules in all 19 EU countries applied for.
Marketing will commence via our European partners in the key territories prior
to the end of this financial year.

The Group also continues to make progress on Vetoryl Capsules in the USA.
Feedback has been received from the FDA on both safety and efficacy, and as a
result we will shortly commence supportive USA based trials to complete the
regulatory application package. The trial work is expected to be completed in
late 2007.

Current Trading

Current trading has continued in line with management expectations, with Group
revenue growth of approximately 11%. This reflects both strong market conditions
and increased market share.

As budgeted, product development expenditure will be significantly higher during
the first half of the current financial year at approximately £0.8 million
(2004: £0.3 million).

We remain confident that Group performance for the financial year ending 30 June
2006 will be in line with management expectations.



Enquiries:
Ian Page, Chief Executive                      Fiona Tooley, Director
Simon Evans, Group Finance Director            Katie Dale, Senior Account Manager
Dechra Pharmaceuticals PLC                     Citigate Dewe Rogerson
Tel: [phone]                              Tel: [phone]
Mobile: [phone] (IP) or 07775 642220 (SE) Mobile: [phone] (FMT)
www.dechra.com





                      This information is provided by RNS
            The company news service from the London Stock Exchange